Hidradenitis Suppurativa Market Report 2025

The hidradenitis suppurativa market size has grown strongly in recent years. It will grow from $1.16 billion in 2024 to $1.25 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to increased diagnosis awareness, limited treatment options, advancements in dermatology, rising disease prevalence, patient advocacy initiatives.

The hidradenitis suppurativa market size is expected to see strong growth in the next few years. It will grow to $1.63 billion in 2029 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to biologic therapies development, precision medicine approaches, clinical trial expansion, global initiatives and funding, healthcare policy support. Major trends in the forecast period include advanced immunomodulatory therapies, telemedicine and remote monitoring, patient-centric care, minimally invasive surgical interventions, personalized lifestyle recommendations.

The increasing prevalence of skin diseases is expected to drive the growth of the hidradenitis suppurativa market moving forward. Skin diseases encompass a wide range of issues, including those caused by bacterial, viral, and fungal infections, allergic reactions, skin cancers, and parasites. Hidradenitis suppurativa (HS), a chronic and severe skin condition, is prompting the development of new products and services for its management due to heightened awareness, accurate diagnosis, a growing patient population, and advancements in research. For instance, in January 2024, the American Cancer Society, a U.S.-based non-profit organization focused on cancer elimination, projected 108,270 reported cases of skin cancer, marking a 3.2% increase from the 104,930 cases recorded in 2023. Thus, the rise in skin disease prevalence is driving the growth of the hidradenitis suppurativa market.

The upswing in healthcare expenditure serves as a catalyst for the expansion of the hidradenitis suppurativa market in the future. Healthcare expenditure encompasses all costs associated with providing health services, including aspects such as family planning, nutrition, and emergency assistance with a primary focus on health. Increased healthcare spending facilitates the establishment of comprehensive patient support programs, fostering improved management of hidradenitis suppurativa and positively impacting the quality of care and research in this domain. For instance, according to the 2021-2030 National Health Expenditure (NHE) report by the Centers for Medicare & Medicaid Services in March 2022, national health spending is anticipated to rise by an average of 5.1% annually between 2021 and 2030, projected to reach around $6.8 trillion by 2030. Consequently, the escalation in healthcare expenditure fuels the growth trajectory of the hidradenitis suppurativa market.

The increasing adoption of biologics stands as a prominent trend within the hidradenitis suppurativa market. Leading companies in this sector are heavily investing in research and development endeavors, resulting in the approval of biologic therapies specifically designed for managing hidradenitis suppurativa, thereby solidifying their market position. For example, in June 2023, Novartis AG, a Switzerland-based pharmaceutical company, received approval from the European regulatory authority for Cosentyx, a groundbreaking biologic therapy targeting hidradenitis suppurativa. Cosentyx represents a fully human biologic that effectively inhibits interleukin-17A, a pivotal cytokine associated with the disease. Having undergone clinical research for over 14 years, Cosentyx has established itself as a well-researched medication catering to hidradenitis suppurativa.

Strategic partnerships emerge as a significant trend gaining traction within the hidradenitis suppurativa market. Key industry players are proactively forging strategic alliances to fortify their market positions. For instance, in June 2023, Novartis, a Switzerland-based pharmaceutical company, entered into a partnership with the Emirates Dermatology Society (EDS), based in the UAE, aimed at advancing Hidradenitis Suppurativa awareness within the UAE region. The collaboration's objectives extend to providing crucial insights that aid healthcare providers and policymakers in supporting individuals grappling with this debilitating disease. Novartis and EDS are slated to establish scientific and educational platforms targeting dermatologists and patients within the UAE, fostering awareness and understanding. Furthermore, both organizations are committed to leveraging Real World Evidence (RWE) to capture and generate localized data on hidradenitis suppurativa.

In October 2022, Amgen Inc., a leading biopharmaceutical company based in the United States, successfully acquired ChemoCentryx Inc. for a substantial amount of $3.7 billion. This strategic acquisition allows Amgen to strengthen its market position by incorporating ChemoCentryx's product, TAVNEOS, into its diverse portfolio. TAVNEOS, an FDA-approved complement 5a receptor inhibitor with gastrointestinal restriction, holds significant potential as a complementary therapy for individuals affected by hidradenitis suppurativa. ChemoCentryx Inc. specializes in the development of pharmaceuticals targeting autoimmune and oncology diseases, including conditions such as hidradenitis suppurativa.

Major companies operating in the hidradenitis suppurativa market include Pfizer Inc., Johnson & Johnson, AbbVie Inc., Novartis AG, Eli Lilly and Co Ltd., UCB S.A., Leo Pharma A/S, Almirall S.A., Acelyrin Inc., AnaptysBio Inc., Arcutis Biotherapeutics Inc., Otsuka Pharmaceutical Co. Ltd., Yamo Pharmaceuticals, Bayer AG, AstraZeneca plc, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Chemocentryx, Priovant Therapeutics, Aristea Therapeutics, Samsung Bioepis, Organon, Union Therapeutics, Revance Therapeutics, Dermavant Sciences, Dermira Inc., MedImmune LLC, Taro Pharmaceutical Industries Ltd., Immunic Inc.

North America was the largest region in the hidradenitis suppurativa market in 2024. The regions covered in the hidradenitis suppurativa market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hidradenitis suppurativa market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Hidradenitis suppurativa (HS) is a chronic skin condition characterized by the development of painful lumps deep within the skin, typically occurring in areas where skin rubs against skin, such as the armpits, inner thighs, and groin. These lumps can lead to the formation of abscesses and tunnels beneath the skin.

Various skin conditions associated with hidradenitis suppurativa include folliculitis, pimples, boils, and deep acne. Folliculitis, a common skin condition, arises when hair follicles become inflamed or infected. Treatments for folliculitis encompass creams, pills, and procedures such as laser hair removal. The products utilized for hidradenitis suppurativa treatment include tablets and intravenous (IV) injections, administered through oral and parenteral routes. Treatment modalities involve medications, surgical interventions, photodynamic therapy (PDT), laser treatment, among others. End-users of these treatments include hospitals, specialty clinics, homecare settings, and others.

The hidradenitis suppurativa (HS) research report is one of a series of new reports that provides hidradenitis suppurativa (HS) market statistics, including the hidradenitis suppurativa (HS) industry's global market size, regional shares, competitors with an hidradenitis suppurativa (HS) market share, detailed hidradenitis suppurativa (HS) market segments, market trends and opportunities, and any further data you may need to thrive in the hidradenitis suppurativa (HS) industry. This hidradenitis suppurativa (HS) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hidradenitis suppurativa (HS) market consists of revenues earned by entities providing treatment to axillary-mammary-inguinal hidradenitis suppurativa, follicular hidradenitis suppurativa, gluteal hidradenitis suppurativa, and syndromic hidradenitis suppurativa. The market value includes the value of related goods sold by the service provider or included within the service offering. The hidradenitis suppurativa (HS) market also includes sales of surgery biologics, antibiotics, immunosuppressive drugs, zinc supplements, and retinoids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.